|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
Novel RAF Kinase Inhibitor
Bay 43-9006 Shows Early Signs of Tolerability and Activity in
Phase Ib Combination Trials Reported at ASCO Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago encouraging Phase Ib data from two clinical trials of BAY 43-9006, a novel, investigational RAF kinase inhibitor, in combination with standard chemotherapeutics, as well as final Phase I results that confirm and extend the positive findings presented at international medical meetings in 2002. This novel inhibitor is an orally active small molecule agent currently in Phase II clinical development in a collaboration between Bayer and Onyx. The data describe safety findings and preliminary antitumor activity from multiple Phase Ib chemotherapy combination trials and Phase I single-agent clinical trials. ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||